Antisense technology expolits oligonucleotide analogs to bind to cognate RNA sequences through Watson‐Crick hybridization resulting in the destruction or disablement of the target RNA. Durign the past decade, programs on all fronts has continued and there are satisfactory consensus to all the basic questions.
In this review, progress in the medicinal chemistry and molecular pharmacology of antisense is reviewed. Further, progress in understanding thepharmacokinetic, pharmacodynamic and toxicologic properties of first and second generations antisense drugs is reviewed. Additionally, a summary of clinical data on a significant number of antisense drugs is provided.